<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00037544</url>
  </required_header>
  <id_info>
    <org_study_id>3082B1-306</org_study_id>
    <nct_id>NCT00037544</nct_id>
  </id_info>
  <brief_title>Study Evaluating ReFacto AF in Severe Hemophilia A</brief_title>
  <official_title>An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes
      during prophylaxis treatment, including neoantigenicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Hemophilia A</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ReFacto AF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A (FVIII:C less than or equal to 2% at local laboratory)

          -  Previously treated patients with greater than or equal to 250 exposure days to any
             Factor VIII product

          -  Age greater than or equal to 12 years

          -  History of prophylaxis dosing at least twice per week on any Factor VIII product for
             at least 3 consecutive months within the 2 years prior to study enrollment unless the
             patient completed the previous pharmacokinetic study

          -  Adequate laboratory results

        Exclusion Criteria:

          -  Presence of any bleeding disorder in addition to hemophilia A

          -  Concomitant therapy with immunosuppressive drugs

          -  Current or historical Factor VIII inhibitor

          -  Treatment with any investigational drug or device within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2002</study_first_submitted>
  <study_first_submitted_qc>May 17, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2002</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <keyword>Severe</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

